Abstract:Objective: This guideline provides recommendations for the prevention of Rh D alloimmunization (isoimmunization) in pregnancy, including parental testing, routine postpartum and antepartum prophylaxis, and other clinical indications for prophylaxis. Prevention of red cell alloimmunization in pregnancy with atypical antigens (other than the D antigen), for which immunoprophylaxis is not currently available, is not addressed in this guideline. Target population: All Rh D-negative pregnant individuals at risk for Rh D alloimmunization due to potential exposure to a paternally derived fetal Rh D antigen. Outcomes: Routine postpartum and antepartum Rh D immunoprophylaxis reduces the risk of Rh D alloimmunization at 6 months postpartum and in a subsequent pregnancy. Benefits, harms, and costs: This guideline details the population of pregnant individuals who may benefit from Rho(D) immune globulin (RhIG) immunoprophylaxis. Thus, those for whom the intervention is not required may avoid adverse effects, while those who are at risk of alloimmunization may mitigate this risk for themselves and/or their fetus. Evidence: For recommendations regarding use of RhIG, Medline and Medline in Process via Ovid and Embase Classic + Embase via Ovid were searched using both the trials and observational studies search strategies with study design filters. For trials, the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Database of Abstracts of Reviews of Effects via Ovid were also searched. All databases were searched from January 2000 to November 26, 2019. Studies published before 2000 were captured from the grey literature of national obstetrics and gynaecology specialty societies, luminary specialty journals, and bibliographic searching. A formal process for the systematic review was undertaken for this update, as described in the systematic review manuscript published separately. Validation methods: The authors rated the quality of evidence and strength of recommendations using the SOGC's modified GRADE approach. See Appendix A (Tables A1 for definitions and A2 for interpretations of strong and conditional [weak] recommendations). Intended audience: The intended users of this guideline include prenatal care providers such as obstetricians, midwives, family physicians, emergency room physicians, and residents, as well as registered nurses and nurse practitioners. Tweetable abstract: An updated Canadian guideline for prevention of Rh D alloimmunization addresses D variants, cffDNA for fetal Rh type, and updates recommendations on timing of RhIG administration. Summary statements: RECOMMENDATIONS.

Anti‐D immunization after D positive platelet transfusions in D negative recipients: A systematic review and meta‐analysis

Another piece of the hemolytic disease of the fetus and newborn puzzle after RhD-positive transfusion in trauma resuscitation: the proportion of pregnant women who produce high titer anti-D

Why do RhD negative pregnant women still become anti-D immunized despite prophylaxis with anti-D immunoglobulin?

Transfusing selected RhD negative patients with RhD positive packed red cell concentrates resulted in lower frequency of anti‐D development and saved almost two thousand RhD negative concentrates during 5 years

Antenatal RHD screening to guide antenatal anti-D immunoprophylaxis in non-immunized D- pregnant women

Does high body mass index (>25 kg/m2) or weight (>80 kg) reduce the effectiveness of anti‐D prophylaxis in Rh(D)‐negative pregnant women? A systematic review and meta‐analysis

Guideline No. 448: Prevention of Rh D Alloimmunization

'Old is gold' does conventional test tube method still reign supreme? An immuno‐haematological survey of anti‐D detection and titration in ante‐natal cases among major hospitals across India

RhD‐negative red blood cells can be saved during liver transplantation in RhD‐negative patients due to low risk of alloimmunization against RhD

Receipt of RhD‐positive whole blood for life‐threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti‐D

Anti-D Alloimmunization in Index Pregnancy after Appropriate Rho(D) Immune Globulin Injection in Two Obese Rh-Negative Patients

Not as "D"eadly as once thought - the risk of D-alloimmunization and hemolytic disease of the fetus and newborn following RhD-positive transfusion in trauma

Incidence of formation of anti‐D between patients with and without a history of solid organ transplant

Non-RhD alloimmunization in pregnancy: an updated review

Standard Compared With Extended Red Blood Cell Antigen Matching for Prevention of Subsequent Hemolytic Disease of the Fetus and Newborn: A Systematic Review

Naturally Occurring Anti-D in a Male Blood Donor, Unresolved Mystery

Prevalence of unexpected red blood cell antibodies in pregnant women and follow-up of pregnancy outcome in pregnant women treated with intra-uterine transfusion

Few points on anti-D immunoglobulin administration in Rh-negative pregnant women

Hemolytic disease of the fetus and newborn-a perspective of immunohematology

Red blood cell alloimmunization in transfused patients with myelodysplastic syndromes: a retrospective study from northern China

Maternal red blood cell alloimmunization prevalence in the United States